Given a less than 8% likelihood for a New Drug Approval from first in man clinical trials, drug developers and pharma companies are faced with questions around how to accelerate the discovery and development of new therapeutics. New strategies around use of diagnostics, regulatory engagement, and industry alliances are often insufficient. But the path to NDA is now supported in many cases by in-silico work on top of the traditional endeavors.
Driven by rich clinico-genomic data, such as whole exome sequencing, RNAseq, and patient treatment history, AI technologies and bio simulations are creating a paradigm shift that will is radically transforming drug discovery, clinical trial development, and the acceleration of drug commercialization. This panel will showcase recent examples in digital, AI, and in-silico models that highlight this new reality and the real potential to decrease the timelines around clinical trials, speed up drug development, and ultimately improve patient care.